#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	13756	16S	1529	1529	100.0	16S.l6.c30.ctg.1	1988	677.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1386	1386	C	806	C,A	784,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25274	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3609	694.5	0	.	n	.	0	T695C	SNP	695	695	T	1063	1063	C	791	C,T	766,5	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25274	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3609	694.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1705	1705	A	853	A,G	804,33	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25274	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3609	694.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2339	2339	C	748	C	729	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25274	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3609	694.5	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2965	2965	T	771	T,C	711,44	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25274	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3609	694.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2413	2413	A	747	A	736	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1848	folP	852	852	100.0	folP.l15.c4.ctg.1	1523	119.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1085	1087	AGC	184;184;186	A;G;C	178;175;177	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4894	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3534	137.1	1	SNP	p	S91F	0	.	.	271	273	TCC	584	586	TCC	158;159;163	T;C,T;C	154;147,7;155	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4894	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3534	137.1	1	SNP	p	D95N	0	.	.	283	285	GAC	596	598	GAC	151;149;148	G;A,G,C;C	147;137,7,1;144	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4894	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3534	137.1	1	SNP	p	D95G	0	.	.	283	285	GAC	596	598	GAC	151;149;148	G;A,G,C;C	147;137,7,1;144	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1432	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1355	104.6	0	.	p	.	0	A39T	NONSYN	115	117	GCC	447	449	ACC	163;164;161	A,G;C;C	145,9;159;157	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1432	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1355	104.6	0	.	p	.	0	R44H	NONSYN	130	132	CGC	462	464	CAC	157;156;157	C;A,G;C	151;136,9;152	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1432	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1355	104.6	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	645	647	CAC	160;158;157	C,T;A;C	141,13;150;152	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1432	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1355	104.6	1	SNP	p	G45D	0	.	.	133	135	GGC	465	467	GGC	158;155;155	G;G,A;C	153;146,1;150	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	812	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c30.ctg.1	944	84.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4484	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3099	143.4	1	SNP	p	D86N	0	.	.	256	258	GAC	610	612	GAC	168;169;169	G;A;C	164;161;166	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4484	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3099	143.4	1	SNP	p	S87W	0	.	.	259	261	AGT	613	615	AGT	169;171;171	A,C;G;T	154,10;167;164	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4484	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3099	143.4	1	SNP	p	S87I	0	.	.	259	261	AGT	613	615	AGT	169;171;171	A,C;G;T	154,10;167;164	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4484	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3099	143.4	1	SNP	p	S87R	0	.	.	259	261	AGT	613	615	AGT	169;171;171	A,C;G;T	154,10;167;164	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4484	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3099	143.4	1	SNP	p	S88P	0	.	.	262	264	TCC	616	618	TCC	170;171;171	T;C,A;C	164;166,1;166	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3682	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2772	131.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1569	1571	GGC	179;177;173	G;G;C	174;174;165	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3600	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	150.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1191	1193	GCA	211;212;213	G;C;A,C	200;203;200,7	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3600	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	150.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1194	1196	ATC	212;213;213	A;T;C,G,A	203;206;195,6,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3600	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	150.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1206	1208	GTG	212;209;208	G,A,T;T,C;G,C	198,4,1;197,4;197,3	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3600	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	150.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1206	1208	GTG	212;209;208	G,A,T;T,C;G,C	198,4,1;197,4;197,3	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3600	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	150.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1710	1712	ACC	152;153;155	A;C;C	146;151;150	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3600	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	150.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1764	1766	GCG	145;146;145	G;C,G;G	140;119,2;134	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3600	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	150.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1764	1766	GCG	145;146;145	G;C,G;G	140;119,2;134	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3600	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	150.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1887	1889	GGC	139;138;135	G;G,T;C,T	134;130,1;127,4	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3600	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	150.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1896	1898	GGC	128;126;124	G,A;G;C	115,5;120;117	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3600	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2317	150.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1914	1916	CCG	93;93;90	C,G;C;G,C	88,2;87;77,2	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5028	ponA	2397	2397	99.96	ponA.l15.c30.ctg.1	3200	155.6	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1658	1660	CTG	177;175;175	C,G;T,C;G,T	165,1;152,11;163,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2104	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1843	112.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	537	537	C	137	C	129	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	276	porB1a	984	331	90.45	porB1a.l6.c17.ctg.2	629	15.4	0	.	p	.	0	H217N	NONSYN	649	651	CAT	312	314	AAT	10;10;10	A;A;T	10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	276	porB1a	984	331	90.45	porB1a.l6.c17.ctg.2	629	15.4	0	.	p	.	0	D218N	NONSYN	652	654	GAT	315	317	AAT	12;12;12	A;A;T	12;12;12	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	276	porB1a	984	331	90.45	porB1a.l6.c17.ctg.2	629	15.4	0	.	p	.	0	A222V	NONSYN	664	666	GCT	327	329	GTT	11;11;11	G;T,C;T,C	11;10,1;10,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	276	porB1a	984	331	90.45	porB1a.l6.c17.ctg.2	629	15.4	0	.	p	.	0	V226A	NONSYN	676	678	GTA	339	341	GCA	13;14;14	G;C;A	13;14;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	276	porB1a	984	331	90.45	porB1a.l6.c17.ctg.2	629	15.4	0	.	p	.	0	.	MULTIPLE	700	702	ACT	362	364	GTA	9;9;9	G;T;A	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	276	porB1a	984	331	90.45	porB1a.l6.c17.ctg.2	629	15.4	0	.	p	.	0	D238fs	FSHIFT	712	712	G	374	374	G	14	G	14	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2582	porB1b	1035	1035	95.74	porB1b.l15.c30.ctg.1	1406	179.6	0	.	p	.	0	F135L	NONSYN	403	405	TTT	627	629	CTT	193;192;191	C,G,T;T;T,G	176,7,5;184;178,7	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2582	porB1b	1035	1035	95.74	porB1b.l15.c30.ctg.1	1406	179.6	0	.	p	.	0	R143G	NONSYN	427	429	AGA	651	653	GGA	194;189;190	G,C,A;G,A;A,G	178,6,5;179,7;182,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2582	porB1b	1035	1035	95.74	porB1b.l15.c30.ctg.1	1406	179.6	0	.	p	.	0	G189S	NONSYN	565	567	GGC	789	791	AGC	202;203;206	A,G;G,A;C,G	195,5;195,6;201,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2582	porB1b	1035	1035	95.74	porB1b.l15.c30.ctg.1	1406	179.6	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	855	855	T	172	T	162	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2582	porB1b	1035	1035	95.74	porB1b.l15.c30.ctg.1	1406	179.6	1	SNP	p	G120K	0	.	.	358	360	GGT	582	584	GGT	191;191;194	G,A;G,A;T,G	179,10;180,9;176,9	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2582	porB1b	1035	1035	95.74	porB1b.l15.c30.ctg.1	1406	179.6	1	SNP	p	A121N	0	.	.	361	363	GCC	585	587	GCC	193;191;190	G,A;C,A;C	183,9;179,9;188	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2582	porB1b	1035	1035	95.74	porB1b.l15.c30.ctg.1	1406	179.6	1	SNP	p	A121D	0	.	.	361	363	GCC	585	587	GCC	193;191;190	G,A;C,A;C	183,9;179,9;188	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8780	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5014	173.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2066	2068	AAT	193;191;192	A,C;A;T	182,6;187;186	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1012	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1010	99.2	1	SNP	p	V57M	1	.	.	169	171	ATG	442	444	ATG	195;198;197	A;T;G,C,A	195;196;191,1,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
